Pipeline Background Image

Hematology Malignancies (Targeted Oncology)

STAGE
PROGRAM
SPECIES
MECHANISM
COMPOUND
POPULATION
MODALITY
Conditionally Approved
Naïve B-Cell Lymphoma
Canine
SINE Inhibitor
Verdinexor
525,000
Small Molecule
Conditionally Approved
Naïve T-Cell Lymphoma
Canine
SINE Inhibitor
Verdinexor
225,000
Small Molecule
Conditionally Approved
Relapsed B-Cell Lymphoma
Canine
SINE Inhibitor
Verdinexor
105,000
Small Molecule
Conditionally Approved
Relapsed T-Cell Lymphoma
Canine
SINE Inhibitor
Verdinexor
44,000
Small Molecule
Mid
Multiple Myeloma
Canine
SINE Inhibitor
Verdinexor
20,000
Small Molecule
Late
Lymphoma
Canine
Undisclosed
Undisclosed
750,000
Small Molecule
Mid
Lymphoma
Feline
SINE Inhibitor
Verdinexor
300,000
Small Molecule

Solid Tumor (Targeted Oncology)

STAGE
PROGRAM
SPECIES
MECHANISM
COMPOUND
POPULATION
MODALITY
Mid
Osteosarcoma
Canine
SINE Inhibitor
Verdinexor
60,000
Small Molecule
Mid
Bladder cancer (TCC)
Canine
SINE Inhibitor
Verdinexor
25,000
Small Molecule
Mid
Hemangiosarcoma
Canine
Bi-Specific Angio
eBAT
600,000
Biologic

Infectious Disease

STAGE
PROGRAM
SPECIES
MECHANISM
COMPOUND
POPULATION
MODALITY
Mid
Feline Infectious Peritonitis
Feline
Protease Inhibitor
GC376
350,000
Small Molecule
Late
Valley Fever
Canine/Feline
Vaccine
CPS-1 mutant
31,000,000
Biologic
Mid
Blastomycosis
Canine/Feline
Vaccine
BAD-1 mutant
29,000,000
Biologic
Mid
Periodontal Disease
Canine/Feline
Vaccine
Undisclosed
100,000,000
Biologic